Tokyo - Delayed Quote • JPY Universal Entertainment Corporation (6425.T) Follow Add holdings 1,040.00 +11.00 +(1.07%) At close: 3:30:00 PM GMT+9 Related News Tesla stock poised for weekly gain as Musk prepares to make full return to company amid alleged drug abuse Tesla stock dropped on Friday but finished higher for the week as a wild week for CEO Elon Musk became even stranger. American Eagle's Q1 loss, Unity upgraded to Buy Yahoo Finance host Josh Lipton tracks today's top moving stocks and biggest market stories in this Market Minute, including a Bloomberg report stating that the Trump administration could broaden its trade restrictions on China's tech sector, American Eagle Outfitters (AEO) reporting a revenue decline on top of a larger-than-expected loss in its first quarter figures, and Jefferies analysts upgrading Unity Software (U) stock to a Buy rating. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute. Gap CEO: The trade war has not stalled our turnaround Gap CEO Richard Dickson says his business is doing just fine, despite the headwinds borne from the Trump trade war. S&P 500 set for major May gains: What investors should watch in June US stocks (^GSPC, ^IXIC, ^DJI) just capped their best May since 1990, according to a Bloomberg report. Though can the rally last? Ritholtz Wealth Management chief market strategist Callie Cox joins Morning Brief to explain why investors may want to stay cautious going into June and ahead of the Federal Reserve's next meeting. To watch more expert insights and analysis on the latest market action, check out more Catalysts here. Fed's preferred inflation gauge shows price increases cooled in April April's PCE report comes as investors are closely watching for any inflationary impacts from President Trump's tariffs. Should crypto be part of your retirement? Here's what to know. The US Labor Department removed guidance discouraging employer-sponsored retirement plans from holding crypto. 401 Financial principal and founder, Tyrone Ross, sits down with Brad Smith to discuss what the change signals about the asset class and outlines what you need to know about investing in crypto for retirement. To watch more expert insights and analysis on the latest market action, check out more Wealth here. Tesla stock higher as robotaxi 'golden age' begins with June 12 start date, Musk officially departing D.C. Tesla stock is on the rise after two big pieces of news came overnight: a reported start date for robotaxi testing and CEO Elon Musk's official government departure. Ulta Beauty earnings, Zscaler outlook: After-Hours Movers Ulta Beauty (ULTA) shares are soaring in extended hours after the cosmetic company beat first quarter earnings estimates. Zscaler (ZS) stock is also gettng a lift into positiver territory after it lifted its full-year earnings outlook. To watch more expert insights and analysis on the latest market action, check out more Asking for a Trend here. Big Tech stocks pare gains as uncertainty looms over Trump tariffs Big Tech stocks pared gains after a brief spike Thursday morning following a US trade court decision that invalidates the vast majority of Trump’s global tariffs. Uber, Tesla robotaxis, Synopsys guidance: Trending Tickers Uber (UBER) shares slide into negative territory on Thursday amid speculation around Tesla's (TSLA) rollout of robotaxis in Austin, Texas, on June 12. Catch Tesla investor Ross Gerber share his thoughts on Waymo's robotaxi model as compared to Tesla's plans. Synopsys (SNPS) suspends its guidance for its current fiscal third quarter and full-year 2025 as it digests new export controls on shipments to China. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. The stock market cheered Trump's tariff setback. But the new reality may be more 'uncertainty.' Wall Street analysts are concerned a recent court decision blocking Trump's tariff rollout only temporarily delays the administration from imposing duties. Ulta Beauty Soars 11.2% on Earnings Beat and Upgraded Outlook Strong Q1 results and raised guidance propel Ulta's stock to its best single-day performance in over a year Top Midday Decliners Medicus Pharma's (MDCX) shares slumped nearly 34% amid heavy trading Friday after the company priced Trump and Musk Speak in Oval Office as the Tesla Leader Departs Washington During his brief stint in the Trump administration, the billionaire left a big mark on the government with his DOGE agency. Why Summit Therapeutics Plunged Today Summit has been a tremendous winner over the past year, as its bispecific antibody lung cancer drug ivonescimab outperformed prior standards of care in phase 3 trials performed in China by Summit's partner Akeso (OTC: AKES.F). While today's results weren't all bad by any means, apparently investors had hoped for more conclusive information about survival rates. With such high expectations, it appears investors are taking profits or de-risking in a big way. Top Midday Gainers Red Robin Gourmet Burgers (RRGB) shares soared 66% amid heavy trading after the company reported a s Analysts Applaud UiPath's AI Traction, But Net New ARR Slide Sparks Caution UiPath, Inc. (NYSE:PATH) shares are trading higher after the company reported better-than-expected first-quarter results, issued second-quarter sales guidance above estimates, and raised its FY26 guidance. On Thursday, the company reported revenue of $356.62 million, versus estimates of $332.87 million, and adjusted EPS of 11 cents, exceeding the estimates of 10 cents. The company raised its fiscal 2026 forecast from a range of $1.52 billion to $1.53 billion to a new range of $1.549 billion to $ Equities Fall Intraday After Trump Accuses China of Violating Trade Pact US benchmark equity indexes were lower intraday after President Donald Trump accused China of violat Sector Update: Tech Stocks Slide Friday Afternoon Tech stocks were in the red Friday afternoon, with the Technology Select Sector SPDR Fund (XLK) down Why Is Nano-Cap BioLineRx Stock Surging On Friday? BioLineRx Ltd’s (NASDAQ:BLRX) poster, which includes new data from the single-arm pilot phase of the investigator-initiated, randomized CheMo4METPANC Phase 2 combination trial, will be presented at the 2025 American Society of Clinical Oncology Annual Meeting. The CheMo4METPANC trial is evaluating motixafortide, cemiplimab, and standard-of-care chemotherapies gemcitabine and nab-paclitaxel, versus gemcitabine and nab-paclitaxel alone, in first-line pancreatic cancer (PDAC). Updated results from Performance Overview Trailing total returns as of 5/30/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) Return 6425.T Nikkei 225 (^N225) YTD +0.39% -4.84% 1-Year -31.61% -0.23% 3-Year -43.13% +38.71%